Skip to content
Sign in
Venture capitalBacked 1 network startup

Lapam Capital

Chinese VC with no profile in our data; investor in Pleryon Therapeutics' Pre-A and Series A.

China
Ticket
—Not published
Assets under management
—
Founded
—
Stages
—
Network startups backed
1
Co-investors
4most often with EFung Capital

How they invest

Unknown; repeat investor in Chinese polymer therapeutics.

Stage and ticket

Pre-A and Series A.

Geography

China (HQ).

What makes them say yes

  • Chinese biotech (inferred)
  • Follow-on behaviour
  • Ophthalmology / regenerative aesthetics

Red flags

  • No published thesis, ticket or stage policy in our data — any approach is a cold qualification call
  • Pitching outside the single sector signal visible in its known deal

Sectors

Not published

Stages

Not published

Geographies

Not published

How to approach

Ask Pleryon's founders for an introduction.

Portfolio

1 network startup · no other company

Pleryon alongside Kaitai, EFung, Zero2IPO, HKUST R&D.

Gaps in the portfolio

  • Unknown thesis

Network startups

  • Pleryon TherapeuticsSWC 2026 Finalist

    HKUST polymer-therapeutics platform entering the clinic in dry eye, with osteoarthritis and aesthetics as follow-on indications.

    China · Biotech & life sciences

Network startups that fit

3 analysed

Tampere spin-off building scalable iPSC-derived corneal cell therapy for limbal stem cell deficiency, targeting first clinical trials around 2027.

Finnish corneal cell therapy — ophthalmology overlap.

20%confidence

Evidence from the records

  • “Pleryon Therapeutics”
  • “Ophthalmic cell therapy (cornea)”
  • “Corneal cell therapy at preclinical stage, clinical trials targeted around 2027”
Intro path
Founder-to-founder intro via Pleryon Therapeutics (network portfolio company of Lapam Capital).
First step
Qualify via Pleryon.

KAIST spin-off developing PEGylated bilirubin BX-001N to prevent acute kidney injury after cardiac surgery, now in phase 2a in Korea.

Korean AKI drug at Series A.

20%confidence

Evidence from the records

  • “Series A”
  • “Drug for acute kidney injury”
  • “BX-001N: phase 1 completed (51 volunteers, Australia), phase 2a under way in Korea (NCT07164833) with KDDF support.”
Intro path
Founder-to-founder intro via Pleryon Therapeutics (network portfolio company of Lapam Capital).
First step
Qualify via Pleryon.

Uruguay-Spain nanobody company pairing single-domain antibodies with local delivery for asthma, colorectal cancer, psoriasis and atopic dermatitis.

Uruguayan nanobodies.

15%confidence

Evidence from the records

  • “Pleryon Therapeutics”
  • “Single-domain antibodies (nanobodies)”
  • “No public evidence of traction found: candidates in discovery/preclinical, no clinical trials.”
Intro path
Founder-to-founder intro via Pleryon Therapeutics (network portfolio company of Lapam Capital).
First step
Low priority.

Analyst reading of 21 Nov 2026, from the public record of the network. Method: analyst-ai.

Co-investors

Most often with EFung Capital, Kaitai Capital, and Zero2IPO

Sources

  1. 1innovationhub.hk/article/pleryon-therapeutics
  2. 2caplight.com/company/pleryon

Profile compiled from public sources. Unknown fields are left empty rather than estimated.